These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 29348807)
1. Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. Michaelides MR; Kluge A; Patane M; Van Drie JH; Wang C; Hansen TM; Risi RM; Mantei R; Hertel C; Karukurichi K; Nesterov A; McElligott D; de Vries P; Langston JW; Cole PA; Marmorstein R; Liu H; Lasko L; Bromberg KD; Lai A; Kesicki EA ACS Med Chem Lett; 2018 Jan; 9(1):28-33. PubMed ID: 29348807 [TBL] [Abstract][Full Text] [Related]
2. Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor. Wilson JE; Patel G; Patel C; Brucelle F; Huhn A; Gardberg AS; Poy F; Cantone N; Bommi-Reddy A; Sims RJ; Cummings RT; Levell JR ACS Med Chem Lett; 2020 Jun; 11(6):1324-1329. PubMed ID: 32551019 [TBL] [Abstract][Full Text] [Related]
3. Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases. Ji Z; Clark RF; Bhat V; Matthew Hansen T; Lasko LM; Bromberg KD; Manaves V; Algire M; Martin R; Qiu W; Torrent M; Jakob CG; Liu H; Cole PA; Marmorstein R; Kesicki EA; Lai A; Michaelides MR Bioorg Med Chem Lett; 2021 May; 39():127854. PubMed ID: 33631370 [TBL] [Abstract][Full Text] [Related]
4. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017 [TBL] [Abstract][Full Text] [Related]
6. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors. Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875 [TBL] [Abstract][Full Text] [Related]
8. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300. Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215 [TBL] [Abstract][Full Text] [Related]
9. E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP. Fax P; Lehmkuhler O; Kuhn C; Esche H; Brockmann D J Biol Chem; 2000 Dec; 275(51):40554-60. PubMed ID: 11006273 [TBL] [Abstract][Full Text] [Related]
10. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021 [TBL] [Abstract][Full Text] [Related]
11. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation. Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323 [TBL] [Abstract][Full Text] [Related]
12. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Balasubramanyam K; Varier RA; Altaf M; Swaminathan V; Siddappa NB; Ranga U; Kundu TK J Biol Chem; 2004 Dec; 279(49):51163-71. PubMed ID: 15383533 [TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors. Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119 [TBL] [Abstract][Full Text] [Related]
14. Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity. Ray S; Sherman CT; Lu M; Brasier AR Mol Endocrinol; 2002 Apr; 16(4):824-36. PubMed ID: 11923478 [TBL] [Abstract][Full Text] [Related]
15. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525 [TBL] [Abstract][Full Text] [Related]
16. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Bordoli L; Hüsser S; Lüthi U; Netsch M; Osmani H; Eckner R Nucleic Acids Res; 2001 Nov; 29(21):4462-71. PubMed ID: 11691934 [TBL] [Abstract][Full Text] [Related]